Immunotherapeutic potential of oncolytic vaccinia virus (Q37895969)

25 August 2017

1 reference

title

Immunotherapeutic potential of oncolytic vaccinia virus (English)

1 reference

25 August 2017

1 reference

1 reference

vaccinia virus

1 reference

Steve H Thorne

1

1 reference

25 August 2017

1 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

50

1 reference

25 August 2017

286-293

1 reference

25 August 2017

2-3

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-011-8211-4

25 August 2017

0 references

cites work

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Combination therapy with conditionally replicating adenovirus and replication defective adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Replicative oncolytic herpes simplex viruses in combination cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Amgen spikes interest in live virus vaccines for hard-to-treat cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Viral vectors for gene-directed enzyme prodrug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Adjuvant IFN alpha2 therapy of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Ligand-directed targeting of genes to the site of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Synergistic antitumor effects of immune cell-viral biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-011-8211-4

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

21 January 2018

1 reference

12 December 2020

Blood compatibility of enveloped viruses

1 reference

12 December 2020

Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.

1 reference

12 December 2020

Chemical control of protein stability and function in living mice.

1 reference

12 December 2020

Differential effects of epidermal growth factor, transforming growth factor-alpha, and vaccinia virus growth factor in the positive regulation of IFN-gamma production

1 reference

12 December 2020

Virus combinations and chemotherapy for the treatment of human cancers.

1 reference

12 December 2020

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

1 reference

12 December 2020

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses

1 reference

12 December 2020

A global approach to tumor immunology.

1 reference

12 December 2020

Poxvirus pathogenesis

1 reference

12 December 2020

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

1 reference

12 December 2020

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

1 reference

12 December 2020

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

1 reference

12 December 2020

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

1 reference

12 December 2020

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.

1 reference

12 December 2020

ONYX-015: clinical data are encouraging

1 reference

12 December 2020

Vaccinia virus and oncolytic virotherapy of cancer.

1 reference

12 December 2020

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production

1 reference

12 December 2020

Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction

1 reference

12 December 2020

10.1007/S12026-011-8211-4

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21717084